Q3 2020 Sales Performance

Pharmaceuticals: revenue breakdown 2019 Revenues of £17.6bn (+0% CER) Therapy Areas Regions Respiratory (+15%) £3.1bn (18%) £8.8bn (50%) Established Pharmaceuticals (-8%) £4.1bn (23%) US (-4%) £7.4bn £4.9bn HIV (+1%) (28%) (42%) Immuno-inflammation (+25%) Oncology (-) Source: GSK Full year 2019 results release - February 2020 All growths at constant exchange rates (CER). Breakdown percentages are approximate £6.0bn (34%) gsk Europe (+2%) International (+4%) 17

View entire presentation